An Improved tBE System and Its Application

By introducing SpRY variants and a dual fusion protein system, the targeting range and editing efficiency of the tBE system are improved, solving the problems of limited targeting range and low editing efficiency of existing tBE systems, and achieving more efficient and safer gene editing results.

CN123107964APending Publication Date: 2026-11-17FUDAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611366967.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-04
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing tBE systems have limited targeting range and low editing efficiency, especially in AT-rich regions or PAM-sparse regions where it is difficult to achieve ideal editing results. They also have off-target effects, affecting the accuracy and safety of gene editing.

Method used

By employing a SpRY variant of the CRISPR effector protein, combined with a dual fusion protein system and dual sgRNA design, and by introducing specific amino acid mutations and RNA aptamer-binding proteins, the activity of cytosine deaminase and spatial control of the repressive domain are enhanced, thereby broadening the target range and improving editing efficiency.

Benefits of technology

It significantly broadened the targeting range of the tBE system, improved editing efficiency and product purity, and demonstrated excellent performance in eukaryotic cell, mouse embryo, ophthalmic and liver models, reducing off-target effects and improving the accuracy and safety of gene editing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107964A_ABST
    Figure CN123107964A_ABST
Patent Text Reader

Abstract

This invention relates to an improved tBE system and its applications. The improved tBE system replaces the traditional CRISPR effector protein with SpRY. Furthermore, by engineering cytosine deaminase and introducing combinatorial point mutations, the etBE-SpRY system is constructed, significantly improving the editing efficiency, targeting range, and product purity of the tBE-SpRY system. The improved tBE system of this invention has demonstrated excellent performance in eukaryotic cell, mouse embryo, ophthalmic, and liver models, providing a new strategy for the development of gene editing tools and showing broad application prospects in disease model construction and gene therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to an improved tBE system and its applications, belonging to the field of life science technology. Background Technology

[0002] Gene editing technology is a revolutionary tool in the field of life sciences, and its core lies in the precise modification of specific genomic sites.

[0003] First-generation gene editing technologies are primarily based on the CRISPR-Cas system (such as CRISPR-Cas9). This system guides the Cas9 nuclease to the target DNA sequence via a single guide RNA (sgRNA), after which the Cas9 protein cleaves the DNA double strand, inducing a DNA double-strand break (DSB). Cells primarily repair DSBs through two repair mechanisms: non-homologous end joining (NHEJ) or homologous targeted repair (HDR). NHEJ repair is highly prone to frameshift mutations or gene knockout, while HDR can be used for precise insertion or replacement of gene fragments. Although the CRISPR-Cas9 system has been widely used in gene knockout and gene knock-in, its mechanism for inducing DSBs has significant limitations: DSBs can trigger cytotoxic reactions such as apoptosis, chromosomal translocation, large-scale DNA deletion, and even p53 pathway activation, severely limiting its safety in clinical settings such as gene therapy. Furthermore, while DSB-induced NHEJ repair is highly efficient, it is difficult to achieve targeted single-base replacements, failing to meet the treatment needs of many genetic diseases (such as those caused by point mutations).

[0004] To address these issues, researchers developed second-generation gene-editing tools—base editors (BEs). Base editors are formed by fusing inactivated Cas proteins (such as dCas9 or nCas9) with cytosine deaminase (or adenine deaminase), enabling direct C→T (cytosine base editor, CBE) or A→G (adenine base editor, ABE) conversions without causing DNA double-strand breaks. This technological breakthrough significantly reduces DSB-related cytotoxicity and shows great potential in areas such as single-base mutation disease modeling and genetic disease treatment. Taking the cytosine base editor as an example, its mechanism of action is as follows: the deaminase deaminates cytosine (C) within the target window to uracil (U), and then the cellular DNA repair mechanism treats U as T for replication or repair, ultimately achieving the C-to-T conversion.

[0005] However, recent studies have shown that base editors can induce significant off-target mutations at the genomic and transcriptomic levels, severely hindering their further application. Specifically: 1) Significant off-target effects; cytosine base editors can cause widespread off-target mutations at the genomic and transcriptomic levels, i.e., C→T transitions occur at non-target locations, seriously affecting the accuracy and safety of gene editing. 2) Limited targeting range; most existing base editors rely on recognizing specific PAM sequences (such as NGG PAM recognized by SpCas9), resulting in many genomic regions not being effectively targeted. 3) Unsatisfactory editing windows and product purity; some editors have editing windows that are too narrow or too wide, and may produce unexpected nucleotide transitions or indels.

[0006] To address these challenges, several research teams in China have jointly developed a transformer-based base editor (tBE). The tBE system utilizes the naturally occurring active domain and repressive domain of mouse cytosine deaminase. By designing a dual sgRNA system (hsgRNA and sgRNA), it achieves spatial control of deaminase activity, thereby significantly reducing off-target effects. Specifically, at non-target sites, the repressive domain binds to the active domain, inactivating the deaminase. Only when both hsgRNA and sgRNA precisely recognize the target site is the repressive domain cleaved by the co-recruited Tobacco etch virus protease, restoring the tBE system's activity. This ingenious design solves the off-target problem at the molecular level and is considered a significant breakthrough in the safety of base editors.

[0007] However, the tBE system still faces several technical bottlenecks, the most significant of which is the limited targeting range. Specifically, the tBE system employs a dual sgRNA design, with an optimal spacing of 34-91 bp between the hsgRNA and sgRNA. This significantly reduces the genomic regions it can target, particularly in AT-rich regions or regions with sparse PAM sequences, making it difficult to achieve ideal editing results. Secondly, the editing efficiency of the tBE system varies considerably across different gene loci and sequence backgrounds, and the editing efficiency at some loci still cannot meet the needs of practical applications.

[0008] Therefore, there is an urgent need in this field to develop an improved tBE system with a wider targeting range and higher editing efficiency. Summary of the Invention

[0009] To address the aforementioned technical problems, the first aspect of this invention provides an improved tBE system comprising: (a) a CRISPR effector protein; (b) a dual fusion protein system comprising an effector fusion protein component and a recruiting fusion protein component; (c) a free protease N-terminal fragment; and (d) a dual sgRNA system comprising sgRNA and hsgRNA and their respective RNA aptamers. The CRISPR effector protein is SpRY, which is based on wild-type SpCas9 with 11 point mutations introduced, while other amino acid residues remain unchanged. The 11 point mutations are A61R, L1111R, D1135L, S1136W, G1218K, E1219Q, N1317R, A1322R, R1333P, R1335Q, and T1337R.

[0010] Regarding "CRISPR effector protein", this application uses SpRY, which is a variant with 11 point mutations introduced on the basis of wild-type SpCas9.

[0011] The "dual fusion protein system" comprises an effector fusion protein component and a recruiting fusion protein component; The “effecton fusion protein assembly” comprises (i) a cytosine deaminase active domain; (ii) a cytosine deaminase inhibitory domain, wherein the inhibitory domain is connected to the active domain via a protease recognition site and the inhibitory domain is capable of inhibiting the deaminase activity of the active domain; and (iii) a first RNA aptamer binding protein.

[0012] The “recruitment fusion protein assembly” includes (a) a second RNA aptamer-binding protein and (b) a C-terminal fragment of a protease.

[0013] In one specific embodiment of this application, the cytosine deaminase active domain is the mouse-derived APOBEC3 cytosine deaminase domain (mA3CDA1).

[0014] In one specific embodiment of this application, the cytosine deaminase inhibitory domain is a mouse-derived deoxycytidine deaminase inhibitory domain (mA3dCDI).

[0015] In one specific embodiment of the invention, the protease is a tobacco etch virus (TEV) protease.

[0016] In one specific embodiment of the present invention, the first RNA aptamer-binding protein is MCP, and the second RNA aptamer-binding protein is N22p. In another specific embodiment of the present invention, the first RNA aptamer is MS2, and the second RNA aptamer is boxB.

[0017] In a preferred embodiment of this application, the effector fusion protein assembly comprises a cytosine deaminase active domain; The cytosine deaminase active domain is a mutant of the mouse-derived APOBEC3 cytosine deaminase domain (mA3CDA1), which introduces a combinatorial point mutation based on the wild-type mA3CDA1. The introduced combined point mutations are selected from any of the following combinations: the combination of point mutations D41E, N69G, E107R and N133R, the combination of point mutations D41E, E107R, N133R and D136K, and the combination of point mutations G34R, E107R, N133R and D136K.

[0018] The inventors of this application further enhanced the editing activity of the tBE-SpRY system by combining enhanced amino acid mutations (mutants of the cytosine deaminase domain).

[0019] After extensive screening and combination, the following three combined mutants were unexpectedly discovered: a combination of point mutations D41E, N69G, E107R and N133R; a combination of point mutations D41E, E107R, N133R and D136K; and a combination of point mutations G34R, E107R, N133R and D136K.

[0020] More preferably, the introduced combined point mutations are a combination of point mutations D41E, E107R, N133R and D136K.

[0021] In a preferred embodiment of this application, the 5′ and 3′ ends of the hsgRNA or sgRNA are modified with 2′-O-methyl or phosphate thioester. Preferably, the hsgRNA or sgRNA has three nucleotides added to its 5′ and 3′ ends.

[0022] In a preferred embodiment of this application, the cytosine deaminase active domain further comprises a uracil DNA glycosidase inhibitor (UGI).

[0023] The second aspect of this application provides an expression construct for the aforementioned improved tBE system.

[0024] In one specific embodiment of this application, the expression construct of the improved tBE system described above is used to express the tBE-SpRY base editing system, and the expression construct comprises: (1) A first polynucleotide encoding an effector fusion protein assembly, the effector fusion protein assembly comprising: (1a) a cytosine deaminase active domain; (1b) a cytosine deaminase repressive domain, the repressive domain being connected to the active domain via a protease recognition site; and (1c) a first RNA aptamer binding protein; (2) A second polynucleotide encoding a recruitment fusion protein component comprising: (2a) a second RNA aptamer-binding protein; and (2b) a C-terminal fragment of a protease; (3) A third polynucleotide encoding the N-terminal fragment of the protease; (4) The fourth polynucleotide encoding the SpRY protein; (5) A first expression cassette encoding sgRNA, said sgRNA comprising a guide sequence complementary to a target sequence and a first RNA aptamer that binds to the first RNA aptamer-binding protein; and (f) A second expression cassette encoding hsgRNA, the hsgRNA comprising a guide sequence complementary to the target sequence and a second RNA aptamer that binds to the second RNA aptamer binding protein.

[0025] In one specific embodiment of this application, at least two of the first polynucleotide, the second polynucleotide, the third polynucleotide, and the fourth polynucleotide are located on the same vector.

[0026] A third aspect of this application provides a kit comprising the above-described system or expression construct, a carrier, delivery reagent, and / or pharmaceutically acceptable excipients for delivering the system or expression construct to cells or a subject.

[0027] In a preferred embodiment of this application, the vector is selected from adeno-associated virus vectors, lentiviral vectors, plasmid vectors, or lipid nanoparticles.

[0028] Preferably, a dual AAV carrier system is used, in which the encoding sequence of the tBE system is split and packaged into two AAV carriers.

[0029] The fourth aspect of this application provides the use of the above-described system or kit in the preparation of drugs or tools for gene editing, disease model construction, or gene therapy.

[0030] In a preferred embodiment of this application, the disease model construction includes mouse disease model construction, preferably mouse ophthalmic, embryonic, or liver disease model construction.

[0031] The fifth aspect of this application provides a gene editing method for non-disease treatment purposes, wherein the gene editing method employs the above-described system, the above-described expression construct, or the above-described kit.

[0032] Existing technologies disclose SpRY (Walton et al., Science, 2020), a Cas9 variant with significantly improved PAM recognition flexibility, capable of recognizing a variety of non-NGG PAM sequences. However, whether SpRY is compatible with the tBE system, and whether it can broaden its targeting range while maintaining the low off-target properties of tBE, has not been reported in any studies. The inventors of this application are the first to introduce SpRY into the tBE system, constructing the tBE-SpRY system and verifying its efficient editing capabilities at both NGG and non-NGG PAM sites.

[0033] The inventors of this application not only broadened the targeting range of the tBE system by replacing SpRY, but more importantly, further engineered cytosine deaminase to construct the etBE-SpRY system, significantly improving the editing efficiency, targeting range, and product purity of the tBE-SpRY system. The improved tBE system of this invention has demonstrated excellent performance in eukaryotic cell, mouse embryo, ophthalmic, and liver models, providing a new strategy for the development of gene editing tools and showing broad application prospects in disease model construction and gene therapy. Attached Figure Description

[0034] Figure 1 A comparison of the editing activity assays of tBE-SpRY and tBE-SpCas9 at the NGG PAM site in HEK293T cells (Figure 1) Figure 1 A is a flowchart of cell experiments; Figure 1 B is a comparison of the editing efficiency of tBE-SpCas9 and tBE-SpRY at 8 NGG PAM gene loci in the HEK293T cell line; Figure 1 C is a statistical graph showing the average editing efficiency of tBE-SpCas9 and tBE-SpRY at 8 NGGPAM gene loci in the HEK293T cell line. Figure 2 The graph shows the editing activity of tBE-SpRY at non-NGG PAM sites in HEK293T cells. Figure 2 A is a graph showing the editing efficiency of tBE-SpCas9 and tBE-SpRY at 24 non-NGG PAM gene loci in the HEK293T cell line; Figure 2 B is a statistical graph showing the average editing efficiency of tBE-SpCas9 and tBE-SpRY at 24 non-NGG PAM gene loci in the HEK293T cell line. Figure 3 Application of tBE-SpRY technology in the construction of albino mouse models ( Figure 3 A represents the mouse coat color phenotype; Figure 3B is a Sanger sequencing peak diagram of genomic DNA target sites at the tail tips of four pure white mice; Figure 3 C represents the target site editing efficiency results for the brain, heart, and liver of four pure white mice; Figure 3 D is the off-target analysis diagram of the sgRNA site; Figure 3 E represents the off-target analysis diagram of hsgRNA sites. Figure 4 The results show the editing efficiency of 15 hsgRNA-sgRNA combinations designed and screened targeting the complement pathway gene C3 in the N2A cell line.

[0035] Figure 5 Application of tBE-SpRY technology in mouse ophthalmic disease models ( Figure 5 Figure A shows the PCR electrophoresis results of retinal pigment epithelial cells isolated from mouse eyes that targeted the retinal pigment epithelium. Figure 5 B shows the fluorescence results of a mouse eyeball patch injected with adeno-associated virus, verifying the feasibility of the subretinal injection adeno-associated virus delivery method; Figure 5 C represents the gene editing efficiency of the target sites in the retinal pigment epithelial cells of mice in the tBE-SpRY treatment group and the EGFP control group. Figure 6 A and Figure 6 B represents the screening results of deaminase single mutants and combined mutants at the CUL3 and EMX1 gene loci, respectively. Figure 7 A graph showing the editing efficiency of QM3 at 12 non-NGG PAM sites in the HEK293T cell line; Figure 8 The image shows the editing performance of the etBE system in HEK293T cells. Figure 8 A is a statistical graph showing the average editing efficiency of etBE and tBE editors at 29 NGG PAM gene loci in the HEK293T cell line; Figure 8 B represents the frequency of base insertion / deletion mutations generated by etBE and tBE at 29 NGG PAM gene loci in the HEK293T cell line. Figure 8 C represents the purity frequency of products generated by etBE and tBE at 29 NGG PAM gene loci in the HEK293T cell line. Figure 8 D is a graph showing the average editing efficiency of etBE and tBE at each of the 29 NGG PAM gene loci in the HEK293T cell line for cytosine.

[0036] Figure 9 To validate the editing capabilities of the etBE system in humanized mouse livers ( Figure 9 Figure A shows the editing efficiency of liver target sites in mice in the etBE experimental group and the PBS control group; Figure 9B represents the off-target analysis results of sgRNA; Figure 9 C represents the off-target analysis results of hsgRNA. Detailed Implementation

[0037] definition: The following provides some definitions that can be used to explain the “Implementation Scheme” section below.

[0038] Regarding "percentages" in the text, it will be specified whether they are volume percentages (%v / v) or weight percentages (%wt). If not specified, they will be weight percentages. Similarly, all proportions are by weight unless otherwise stated. Regarding "concentrations" in the text, it will be specified whether they are mass concentrations (e.g., ng / ml, μg / ml) or molar concentrations (μM).

[0039] As used herein, “about,” “approximately,” and “substantially” should be understood to refer to a number within a certain numerical range, such as -10% to +10% of the mentioned number, preferably -5% to +5% of the mentioned number, more preferably -1% to +1% of the mentioned number, and most preferably -0.1% to +0.1% of the mentioned number.

[0040] Furthermore, all numerical ranges herein should be understood to include all integers or fractions within that range (including endpoint values). Additionally, these numerical ranges should be understood to support claims that involve any number or subset of numbers within that range. For example, disclosures of 1 to 10 should be understood to support ranges of 1 to 8, 3 to 7, 1 to 9, 3.6 to 4.6, 3.5 to 9.9, etc.

[0041] As used herein and in the appended claims, unless the context clearly specifies otherwise, the singular form of a word includes the plural form. Therefore, references to “an,” “a,” and “the” generally include the plural form of the corresponding term. For example, references to “component” or “method” include references to multiple such components or methods. In this invention, descriptions such as “a plurality,” “multiple,” etc., unless otherwise specified, refer to a quantity of two or more.

[0042] Similarly, the terms "including / comprises / contains" are used to interpret them inclusively rather than exclusively. Likewise, the terms "including / comprises / contains" and "or" should be considered inclusive unless the context explicitly prohibits this interpretation. However, the embodiments provided in this disclosure may not contain any elements not expressly disclosed herein. Therefore, a disclosure of one embodiment defined by the term "including / comprises / contains" is also a disclosure of multiple embodiments that are "substantially composed of the disclosed components" and "composed of the disclosed components."

[0043] In this invention, terms such as "preferred," "better," "more suitable," and "ideal" merely describe implementation methods or embodiments with better effects and should be understood not to limit the scope of protection of this invention. In this invention, terms such as "optionally," "optionally," and "optional" mean that something is optional, that is, selected from either "with" or "without" a parallel solution. If multiple "optional" statements appear in a technical solution, unless otherwise specified and without contradiction or mutual constraint, each "optional" statement is independent.

[0044] The term "example / implementation" used herein is for illustrative purposes only and should not be considered exclusive or comprehensive. Any implementation disclosed herein may be combined with any other implementation disclosed herein unless expressly indicated otherwise.

[0045] As used herein, the term "primer" or "PCR primer" refers to a chemically synthesized single-stranded oligonucleotide designed to anneal to a specific site on a DNA template molecule. Primers in PCR are not limited in their use; they are used to initiate DNA synthesis. In one embodiment, the primer is a DNA molecule. In one embodiment, the primer is an RNA molecule. In one embodiment, the primer contains 6 to 70 nucleotides. In one embodiment, the primer contains 10 to 50 nucleotides. In one embodiment, the primer contains 15 to 30 nucleotides. In one embodiment, the primer contains 18 to 25 nucleotides. In one embodiment, the primer contains at least 6 nucleotides. In one embodiment, the primer contains at least 10 nucleotides. In one embodiment, the primer contains at least 15 nucleotides. In one embodiment, the primer contains at least 20 nucleotides. In one embodiment, the primer is a forward primer. In one embodiment, the primer is a reverse primer.

[0046] The term "forward primer" used in this article can hybridize with either the antisense or sense strand of the DNA template, while "reverse primer" hybridizes with either the sense or antisense strand of the DNA template.

[0047] The term "qPCR" used in this article refers to quantitative polymerase chain reaction (PCR). qPCR is used to quantify nucleic acid molecules in a given sample. qPCR can be performed using a fluorescent dye that binds to a DNA template. During each cycle of thermal cycling, the dye binds to the newly formed DNA template, resulting in more measurable fluorescence. The fluorescence signal increases proportionally to the amount of replicated DNA, thus enabling quantification.

[0048] The present invention will be further illustrated by the following examples, but the present invention is not limited to these specific embodiments.

[0049] Example 1: Construction of the tBE-SpRY system and verification of its eukaryotic cell editing activity The steps are as follows: 1. Construction of expression carrier 1-1 SpRY was constructed by introducing 11 point mutations (A61R, L1111R, D1135L, S1136W, G1218K, E1219Q, N1317R, A1322R, R1333P, R1335Q, and T1337R) into SpCas9 through multiple rounds of PCR, and the introduced amino acid mutations were verified to be correct by Sanger sequencing results.

[0050] 1-2 In this study, the tBE-V5-mA3 plasmid was constructed according to the experimental protocol provided by the Chen Jia research group at ShanghaiTech University (Wang et al., Nature Cell Biology, 2021).

[0051] The following are the specific experimental steps: (1) hsgRNA, sgRNA and primer design. First, we designed the sgRNA sequence for the target gene using the BE-Designer online software, and designed the hsgRNA within the 34-91 nt window upstream of the sgRNA. The hsgRNA and sgRNA target the same DNA strand. Based on the designed hsgRNA and sgRNA sequences, corresponding forward and reverse primers were designed.

[0052] (2) Amplification of the insert fragment. Using pUC57-sgRNA-MS2-U6 plasmid as a template, the designed primers were used to amplify the insert fragment containing the hsgRNA-MS2-U6-sgRNA element. The PCR product (~400 bp) was then recovered and purified. (3) Golden Gate Cloning. BsmBI-v2 is a Type IIS restriction endonuclease whose cleavage sequence is outside the recognition sequence. Based on this characteristic, enzyme digestion and enzyme ligation reactions can be performed simultaneously. The Golden Gate cloning system is shown below:

[0053] Table 1 Kinmen Cloning System The Golden Gate cloning reaction conditions are as follows: Step 1: 37℃ for 5 minutes; Step 2: 16℃ for 10 minutes, 37℃ for 15 minutes; repeat this step 10 times. Step 3: 80℃ for 15 minutes; (4) Perform the conversion according to the instructions for use of commercially available competent cells; (5) Select single clones for sequencing, select positive clones for amplification culture and extract plasmids.

[0054] 2. Cell Culture and Transfection The HEK293T and N2a cells involved in this study were both adherent cells, cultured in complete culture medium (with 10% fetal bovine serum and 1% streptomycin-penicillin added); for specific steps, please refer to the reference article (Chen et al., Molecular Therapy Nucleic Acids, 2026).

[0055] 3. Target site design and sequencing analysis (1) First round of PCR: First, primers for the corresponding sites are designed using the Primer3 online software, requiring an annealing temperature of 55-65 degrees Celsius and a product length of 160-270 bp. Among them, the 5' end of the forward primers designed by the software needs to be additionally added with adapter sequences, and the 5' end of the reverse primers also needs to be added with adapter sequences. These two adapter sequences are respectively contained in the Illumina sequencing platform Read 1 and Read 2 sequencing primers, and at the same time provide primer binding sites for the second round of PCR amplification. (2) Second round PCR: The first round PCR product was used as a template for the second round of amplification. P5 and P7 adapters from the Illumina sequencing platform were added to both sides of the first round product, along with the index region molecular library. Primer sequences for the P5 adapter were added in the second round of PCR amplification. The P7 primer sequence was used in the second round of PCR amplification. After PCR, the second round PCR product was subjected to agarose gel electrophoresis to confirm that the band size met expectations (300-400 bp). The product was then purified by gel extraction and sent to the sequencing company. (3) NGS data were analyzed using CRISPResso2 software with default parameters.

[0056] tBE and SpRY compatibility verification (NGG PAM site) See Table 2 below for the gene names of the tested NGG PAM sites, the sequences of the two sgRNAs used, and the corresponding PAM sequence information. In this study, the inventors chose these sites because they are sites that have been previously reported by Professor Jia Chen's research group at ShanghaiTech University, where classical tBE can achieve efficient editing (Wang et al., Nature Cell Biology, 2021).

[0057] Table 2 NGG PAM site information

[0058] See the verification results. Figure 1This is a comparison of the editing activity assays of tBE-SpRY and tBE-SpCas9 at the NGG PAM site in HEK293T cells.

[0059] in, Figure 1 A is a flowchart of the tBE-SpRY (and tBE-SpCas9) cell experiment; from Figure 1 As can be seen from A, the process includes the following steps in sequence: construction of tBE-V5-mA3 plasmid, transfection into HEK293T cells, selection with the addition of puromycin, collection of genomic DNA for the first and second rounds of PCR amplification, and finally next-generation sequencing analysis. The entire process is described in detail in Example 1 of this application.

[0060] Figure 1 B is a comparison of the editing efficiency of tBE-SpCas9 and tBE-SpRY at eight NGG PAM gene loci in the HEK293T cell line. In this bar chart, light blue bars represent the results of tBE-SpCas9, and dark blue bars represent the results of tBE-SpRY. The horizontal axis is labeled with the eight genes FANCF, VA1-B, SPI1-F, DNMT3B, V1A, SPI1-C, RAG1-B, and RAG2-B. On the horizontal axis, C6, C7, and C8 for FANCF represent the cytosine bases located at positions 6, 7, and 8 of the corresponding sgRNA sequence of the FANCF gene (PAM is located at positions 21-23). ​​Here, C represents cytosine, and the numbers are the site numbers set by the inventors for easy identification. The same applies to the other seven genes. The vertical axis, "C-to-T editing frequency (%)", represents the editing efficiency of C→T conversion.

[0061] Figure 1 C is a statistical graph showing the average editing efficiency of tBE-SpCas9 and tBE-SpRY at eight NGG PAM gene loci in the HEK293T cell line.

[0062] from Figure 1 According to the statistical results of C, the editing activity of tBE-SpRY at the NGG PAM site in HEK293T cells was not significantly different from that of tBE-SpCas9.

[0063] Validation of tBE-SpRY targeting range at non-NGG PAM sites See Table 3 below for the gene names of the non-NGG PAM sites tested, the sequences of the two sgRNAs used, and the corresponding PAM sequence information. These sgRNA sequences for non-NGG PAM gene sites were previously reported by Benjamin Kleinstiver's team at Harvard University as sites where SpRY can efficiently edit (Walton et al., Science, 2020). The inventors of this application selected eight of these sgRNAs and designed three corresponding hsgRNAs for each sgRNA, resulting in a total of 24 hsgRNA-sgRNA combinations. The hsgRNA design principles followed the experimental protocol of Jia Chen's research group at ShanghaiTech University (Wang et al., Nature Cell Biology, 2021).

[0064] Table 3. Information on non-NGG PAM gene loci

[0065] See the verification results. Figure 2 , Figure 2 A comparison of the editing activity assays of tBE-SpRY and tBE-SpCas9 at non-NGG PAM sites in HEK293T cells.

[0066] in, Figure 2 A is a comparison of the editing efficiency of tBE-SpCas9 and tBE-SpRY at 24 non-NGG PAM gene loci in the HEK293T cell line; in this bar chart, light blue bars represent the results of tBE-SpCas9, and dark blue bars represent the results of tBE-SpRY; ​​the horizontal axis is labeled with eight genes including CUL3 (see the first column of Table 3), and the vertical axis “C-to-T editing frequency (%)” represents the editing efficiency of C→T conversion.

[0067] Figure 2 B is a statistical graph showing the average editing efficiency of tBE-SpCas9 and tBE-SpRY at 24 non-NGG PAM gene loci in the HEK293T cell line.

[0068] from Figure 2 According to the statistical results of B, tBE-SpRY is significantly better than tBE-SpCas9 in terms of editing efficiency at non-NGG PAM gene sites.

[0069] Example 2: Gene editing and phenotypic validation of the tBE-SpRY system in mouse embryos. Target site design and hsgRNA-sgRNA combination screening See Table 4 below for nine hsgRNA-sgRNA combinations designed targeting the tyrosinase gene. All sgRNAs and hsgRNAs were designed by the inventors of this application.

[0070] Table 4. Information on hsgRNA and sgRNA of tyrosinase gene

[0071] 2. In vitro transcription and chemical modification of mRNA and sgRNA mRNA in vitro transcription: (1) Preparation of in vitro transcription template.

[0072] The T7 promoter was added to the 5ʹ end of the start codon by PCR, and 80 nt polyA was added to the 3ʹ segment of the stop codon. Taking the amplification of the SpRY coding sequence as an example, the forward and reverse primer sequence information used in the PCR amplification to prepare the in vitro transcription template can be found in the literature (Chen et al., Molecular Therapy Nucleic Acids, 2026).

[0073] After the PCR reaction was completed, the PCR product was recovered by gel extraction, purified, and then used for downstream in vitro transcription experiments.

[0074] (2) In vitro transcription. Two modifications were made to the NEB in vitro transcription kit instructions: firstly, a cap analog was added to the in vitro transcription reaction to enhance mRNA translation efficiency; secondly, all UTPs were replaced with N1-Me-pUTPs to reduce cellular immunogenicity. The in vitro transcription system is shown in the table below: Table 5 In vitro transcription reaction system

[0075] Reaction conditions: Incubate at 37 °C for 2 hours; then add 1 µL DNase I to digest the DNA template and incubate at 37 °C for 15 minutes; (3) Purify mRNA according to the NEB RNA purification kit instructions. Note that the maximum capacity of the purchased column is only 50 µg, while an in vitro transcription reaction can produce about 150 µg of mRNA. Therefore, three adsorption columns are needed for one in vitro transcription reaction for recovery. Taking one in vitro transcription reaction as an example, add 110 µL of nuclease-free water to 40 µL of in vitro transcription reaction solution and mix well; add 300 µL of Buffer BX and mix well; then add 450 µL of anhydrous ethanol and mix well; transfer the mixture to three columns (add an average of 300 µL of the mixture to each column), centrifuge at 12,000 rpm for 1 minute at room temperature; add 500 µL of Buffer WX and centrifuge at 12,000 rpm for 1 minute at room temperature; wash again with Buffer WX; add 20-100 µL of nuclease-free water for elution. Quantify using a NanoDrop 2000 spectrophotometer, aliquot and freeze at -80 °C.

[0076] sgRNA and hsgRNA modification patterns: The inventors of this application chemically synthesized hsgRNA and sgRNA modified with 2′-O-methyl and phosphate (PS). Literature (Hendel et al., 2015, Nature Biotechnology; Qiu et al., 2021, Proceedings of the National Academy of Sciences) has confirmed that such modifications significantly enhance sgRNA stability and improve the editing efficiency of the CRISPR system. Therefore, in this study, the inventors adopted the same modification strategy (adding 2′-O-methyl and phosphate to the 5′ and 3′ ends of hsgRNA and sgRNA).

[0077] 3. Mouse embryo microinjection and transplantation 3.1 The specific procedures for the embryo microinjection experiment involved in this study are as follows: (1) Preparation of fertilized eggs. Five 4-week-old female C57BL / 6J mice were selected and injected intraperitoneally with pregnant mare serum at 22:00. 48 hours later, human chorionic gonadotropin was injected intraperitoneally. The mice were then caged with male mice. The next morning, female mice with vaginal plugs were selected to collect fertilized eggs. The female mice were euthanized by cervical dislocation. The abdominal cavity was opened, and the complete oviduct and a small section of the uterus were cut off and placed in the operating solution. The dilated part of the oviduct was located under a dissecting microscope and torn open with a 1 mL syringe needle. The fertilized eggs were then transferred to the operating solution containing 1 mg / mL hyaluronidase and washed 3 times. Then, they were transferred to fresh operating solution and washed repeatedly. Finally, the fertilized eggs were transferred to KSOM medium, covered with mineral oil, and placed in a carbon dioxide incubator. After the pronuclei of the eggs developed, they could be microinjected.

[0078] (2) Pronuclear injection. For specific procedures, refer to the literature (Chen et al., Molecular Therapy NucleicAcids, 2026).

[0079] 3.2 The embryo transfer procedures involved in this study were described in the reference (Chen et al., Molecular Therapy Nucleic Acids, 2026). The experiments involving fasting of mice, collection of liver tissue and blood were conducted according to the experimental protocols reported in the prior art (Wang et al., Nature Cell Biology, 2021; Rothgangl et al., Nature Biotechnology, 2021).

[0080] 4. Results 4.1 Results of Observation on Phenotypic Characteristics of Offspring Mice Figure 3 A represents the mouse coat color phenotype; such as Figure 3 As shown in Figure A, four pure white mice and one black and white mouse were obtained, confirming that the offspring mice have an albinism phenotype.

[0081] 4.2 Genotype Analysis Results Figure 3 B shows the Sanger sequencing peak diagram of the tail tip genomic DNA target sites of four pure white mice (VS four wild-type mice); as shown. Figure 3 The B Sanger sequencing results show that tBE-SpRY introduces the TAG early stop codon (marked by a gray box), while wild-type mice use TGG tryptophan.

[0082] Figure 3C represents the editing efficiency results for target sites in the brain, heart, and liver of four pure white mice. The vertical axis, "C-to-T editing frequency (%)", represents the editing efficiency of the C→T conversion. Figure 3 As shown in C, NGS sequencing results demonstrated that near 100% editing occurred at target sites in the heart, liver, and brain of pure white mice; since the heart, brain, and liver develop from different germ layers, this demonstrates the highly consistent editing efficiency of tBE-SpRY in organs derived from different germ layers.

[0083] 4.3 Results of Off-Target Effect Assessment Figure 3 D is the off-target analysis diagram of the sgRNA site; Figure 3 E is the off-target analysis diagram of hsgRNA sites. On the horizontal axis, sg1 represents the sgRNA sequence used in this study (see Table 4); OT1~OT20 represent the 20 off-target sites associated with sgRNA predicted by the software; Figure 3 E is the off-target analysis diagram of hsgRNA sites; on the horizontal axis, hsg2 represents the hsgRNA sequence used in this study (see Table 4); OT1-OT20 represent the 20 off-target sites related to hsgRNA predicted by the software.

[0084] like Figure 3 D and Figure 3 As shown in E, no significant off-target mutations were detected at the off-target sites associated with the sgRNA and hsgRNA used, confirming that tBE-SpRY has good specificity in the field of constructing mouse disease models.

[0085] Example 3: An Attempt to Apply tBE-SpRY in a Mouse Model of Ophthalmic Diseases 1. Subretinal injection experiment: The experimental steps are as follows. For specific procedures, please refer to the literature (Chen et al., Molecular Therapy Nucleic Acids, 2026): 2. Retinal pigment epithelial cell isolation experiment: For specific operational details, please refer to the literature (Chen et al., Molecular Therapy Nucleic Acids, 2026): 3. In order to determine the optimal hsgRNA-sgRNA combination targeting C3, the inventors of this application designed 15 hsgRNA-sgRNA combinations targeting the mouse complement pathway gene C3 (Complement component 3), and screened them in the mouse cell line N2a, finally identifying the optimal combination hsgRNA10-sgRNA49.

[0086] Table 6. Selection of gene loci for complement pathway

[0087] See results Figure 4 The graph shows a comparison of the gene editing efficiency of these 15 hsgRNA-sgRNA combinations in the mouse cell line N2a. It can be seen that hsgRNA10-sgRNA49 has the highest editing efficiency, indicating that the tBE-SpRY method of this application can achieve an editing efficiency of about 30% in mouse cell lines.

[0088] See Figure 5 This refers to the application of tBE-SpRY technology in mouse ophthalmic disease models.

[0089] Among them, see Figure 5 A. PCR electrophoresis results of target sites on retinal pigment epithelial cells isolated from mouse eyes. The figures show the electrophoresis results of PCR products from target sites on retinal pigment epithelial cells of eight mice that received AAV injection, labeled 1-8. Label 9 is the positive control using N2A cell samples as templates; M represents the standard, with band sizes from bottom to top being 100, 200, 300, 400, 500 (highlighted), 600, 700, 800, 900, and 1000 bp.

[0090] Figure 5 B shows the fluorescence results of a mouse eye patch injected with adeno-associated virus; this result verifies the feasibility of the subretinal injection adeno-associated virus delivery method. Figure 5 C represents the gene editing efficiency results at the target site in the retinal pigment epithelial cells of mice in the tBE-SpRY treatment group and the EGFP control group; from Figure 5 The comparison results of C show that tBE-SpRY can be used for gene editing in mouse ophthalmic disease models.

[0091] Example 4: Engineering modification of cytosine deaminase to improve the editing efficiency of the tBE-SpRY system This study targeted point mutations in the cytosine deaminase within the tBE-SpRY system, screening for 18 enhanced single-amino acid mutants. Subsequently, we further enhanced the editing activity of the tBE system by combining enhanced amino acid mutations, ultimately identifying the QM1, QM3, and QM5 mutants, whose editing efficiency was significantly higher than that of the wild-type control group.

[0092] All point mutation plasmids used in this study were constructed according to the instructions of the commercially available kits. The construction method of point mutation plasmids is described below using the DNMT3B-tBE-V5-mA3(G34R) plasmid as an example.

[0093] (1) Primer design. The Takara online software was used to design primers carrying point mutations. Taking the G34R mutation as an example, the alanine at position 34 was mutated to arginine.

[0094] (2) Reverse PCR amplification. Using the primers designed above, and with the DNMT3B-tBE-V5-mA3 plasmid as a template, reverse PCR amplification was performed. The PCR amplification system is shown in Table 7 below: Table 7 Reverse PCR Amplification System

[0095] The PCR reaction conditions are as follows: Pre-denaturation: 94 °C for 2 minutes; denaturation: 98 °C for 10 seconds; annealing: 58 °C for 30 seconds; extension: 68 °C for 5 minutes; repeat this step 10 times; final extension: 68 °C for 5 minutes; store at 4 °C.

[0096] (3) Remove template plasmid. Add 1 µL of DpnI (provided in the kit) to the above PCR system. Incubate at 37 °C for 1 hour; (4) Phosphorylation and self-ligation of PCR products. The phosphorylation and ligation system is shown in Table 8 below: Table 8 Phosphorylation and Linkage Systems

[0097] Reaction conditions: Incubate at 16 °C for 1 hour.

[0098] Transform the above products.

[0099] See Figure 6 The results show the screening results for single and combined mutants of deaminase.

[0100] The patent applicant employed a rationally designed strategy to perform amino acid point mutations on the cytosine deaminase mA3CDA1 used in the tBE-SpRY system. The X-axis represents different single mutants and combined mutants, while the Y-axis represents the fold change in editing efficiency of different deaminase variants relative to the wild-type deaminase variant. The dashed line on the Y-axis represents wild-type deaminase variant data (Y=1). C4 and C5 are the 4th and 5th cytosine residues on the sgRNA at the CUL3 gene locus, and PAM is located at positions 21-23.

[0101] Through experiments, the patent applicant identified 18 beneficial mutations that can enhance deaminase activity (G34R, D41E, N66K, N69G / R, I70K / R, C75R, F106R, E107R, N133H / K / R, V134K / R, D136N / K / R).

[0102] Furthermore, the six best-performing mutants were selected, and the combined mutants obtained by combining amino acid mutations had a cumulative effect, further enhancing the activity of deaminase.

[0103] Figure 6 A and Figure 6 B represents the screening results of deaminase single mutants and combined mutants at the CUL3 and EMX1 gene loci, respectively.

[0104] comprehensive Figure 6 A and Figure 6 According to the results of B, the five mutant combinations D41E / N69G / E107R / N133R (labeled as QM1 mutant), D41E / N69G / N133R / D136K (labeled as QM2 mutant), D41E / E107R / N133R / D136K (labeled as QM3 mutant), G34R / D41E / N133R / D136K (labeled as QM4 mutant), and G34R / E107R / N133R / D136K (labeled as QM5 mutant) showed the best overall performance and will be further evaluated together.

[0105] See Figure 7 The results show the comparison of editing efficiency of wild-type deaminase and QM1-QM5 at 12 non-NGG PAM sites in the HEK293T cell line.

[0106] The X-axis represents different deaminase variants, and the Y-axis represents the average C>T editing efficiency. The results showed that the average editing efficiency of QM1, QM3, and QM5 was significantly higher than that of the wild type, with QM3 having the highest average editing efficiency.

[0107] The inventors of this application have named the tBE-SpRY system using QM1, QM3, or QM5 deaminase variants as the engineered tBE system (etBE-SpRY, also referred to as etBE in the accompanying drawings). Taking QM3 as an example, we compared the classic tBE-SpRY and the engineered variant etBE-SpRY at 29 gene loci in the HEK293T cell line.

[0108] See Figure 8 This compares the editing performance of etBE-SpRY and tBE-SpRY at 29 gene loci. Figure 8 A represents the average editing efficiency of both; Figure 8 B represents the average DNA insertion / deletion mutation frequency mediated by both factors. Figure 8 C represents the average purity data of the two products; Figure 8 D is a graph showing the average editing efficiency of the two at each cytosine site.

[0109] Figure 8Results A show that etBE-SpRY has a significantly higher average editing efficiency than tBE-SpRY; Figure 8 Results B showed that the DNA insertion and deletion frequencies mediated by both methods were comparable. Figure 8 The C results show that etBE-SpRY has a higher average product purity; Figure 8 The D results display for etBE-SpRY features a wider editing window.

[0110] Figure 9 The figure shows the experimental results of etBE-SpRY delivery to humanized mice. Five humanized mice received etBE-SpRY treatment, and five humanized mice received the same volume of PBS phosphate buffer as a control. etBE-SpRY was delivered via dual AAV.

[0111] Figure 9 A represents the liver editing efficiency of 5 experimental mice and 5 control mice (samples were collected 4 weeks after injection). etBE-SpRY mediated a significantly higher editing efficiency than the control group, with an average of 18.45%.

[0112] Figure 9 B and Figure 9 C represents the off-target analysis results of sgRNA and hsgRNA in humanized mice.

[0113] The sgRNA sequence is TGCCAGCGCCTGGCGAGGGC (Sequence 1), and the PAM is TGG; the hsgRNA sequence is TGCTGCTGCCCCTGGCGGGT (Sequence 2), and the PAM is GGG.

[0114] The horizontal axis represents the corresponding target sites for PCSK9 used in this study, sgRNA and hsgRNA. OT1-OT10 represent the 10 predicted off-target sites associated with sgRNA and hsgRNA; the vertical axis represents editing efficiency. The results showed that mice treated with etBE-SpRY did not produce significantly more off-target editing than the control group.

[0115] In summary, the etBE-SpRY system using the deaminase variant of this application exhibits significantly higher average editing efficiency, higher average product purity, and a wider editing window compared to the tBE-SpRY system using wild-type deaminase, without producing off-target editing.

[0116] It should be understood that although this specification describes embodiments, not every embodiment contains only one independent technical solution. This way of describing the specification is only for clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment can also be appropriately combined to form other embodiments that can be understood by those skilled in the art.

[0117] The detailed descriptions listed above are merely specific descriptions of feasible embodiments of the present invention, and are not intended to limit the scope of protection of the present invention. All equivalent embodiments or modifications made without departing from the spirit of the present invention should be included within the scope of protection of the present invention.

Claims

1. An improved tBE system comprising: (a) a CRISPR effector protein; (b) a dual fusion protein system comprising an effector fusion protein component and a recruiting fusion protein component; (c) an N-terminal fragment of a free protease; and (d) a dual sgRNA system comprising sgRNA and hsgRNA and their respective RNA aptamers. Its features are, The CRISPR effector protein is SpRY, which is based on wild-type SpCas9 with 11 point mutations introduced, while other amino acid residues remain unchanged; the 11 point mutations are A61R, L1111R, D1135L, S1136W, G1218K, E1219Q, N1317R, A1322R, R1333P, R1335Q, and T1337R; The effector fusion protein assembly includes a cytosine deaminase active domain. The cytosine deaminase active domain is a mutant of the mouse-derived APOBEC3 cytosine deaminase domain (mA3CDA1), which introduces a combinatorial point mutation based on the wild-type mA3CDA1. The introduced combined point mutations are selected from any of the following combinations: the combination of point mutations D41E, N69G, E107R and N133R, the combination of point mutations D41E, E107R, N133R and D136K, and the combination of point mutations G34R, E107R, N133R and D136K.

2. The system as described in claim 1, characterized in that: The introduced combined point mutations are a combination of point mutations D41E, E107R, N133R and D136K.

3. The system as described in claim 2, characterized in that: The hsgRNA or sgRNA is modified with 2′-O-methyl or thiophosphate at its 5′ and 3′ ends; Preferably, the hsgRNA or sgRNA has three nucleotides added to its 5′ and 3′ ends.

4. The expression construct of the improved tBE system as described in any one of claims 1-3.

5. A reagent kit, characterized in that: The kit comprises the system as described in any one of claims 1-3 or the expression construct as described in claim 4, a carrier, delivery reagent, and / or pharmaceutically acceptable excipients for delivering the system or the expression construct to cells or a subject.

6. The kit as described in claim 4, characterized in that: The vector is selected from adeno-associated virus vectors, lentiviral vectors, plasmid vectors, or lipid nanoparticles.

7. Use of the system of any one of claims 1-3, the expression construct of claim 4, or the kit of any one of claims 5-6 in the preparation of a medicament or tool for gene editing, disease model construction, or gene therapy.

8. The use as described in claim 7, characterized in that: The disease model construction includes mouse disease model construction, preferably mouse ophthalmic, embryonic, or liver disease model construction.

9. A gene editing method for non-disease treatment purposes, characterized in that: The gene editing method employs the system described in any one of claims 1-3, the expression construct described in claim 4, or the kit described in any one of claims 5-6.